Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Glens Falls Hospital — Glens Falls, New York
- Northwell Health Cancer Institute at Huntington — Greenlawn, New York
- Northwell Health/Center for Advanced Medicine — Lake Success, New York
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in New York: - Northwell Health Imbert Cancer Center — Bay Shore, New York
- Maimonides Medical Center — Brooklyn, New York
- NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Hematology Oncology Associates of CNY at Camillus — Camillus, New York
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in New York: - NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
- Nyack Hospital — Nyack, New York
- Stony Brook University Medical Center — Stony Brook, New York
- Dickstein Cancer Treatment Center — White Plains, New York
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in New York: - NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- The Cancer Institute at Saint Francis Hospital — East Hills, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Mount Sinai Chelsea — New York, New York
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in New York: - New York Oncology Hematology (NYOH) — Amsterdam, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Hematology Oncology Associates of Central New York, PC — East Syracuse, New York
- Northwell Health — Lake Success, New York
- Laura and Isaac Perlmutter Cancer Canter — New York, New York
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in New York: - The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0135) — New York, New York
- Icahn School of Medicine at Mount Sinai ( Site 0123) — New York, New York
- Memorial Sloan Kettering Cancer Center ( Site 0067) — New York, New York
- Clinical Research Alliance ( Site 0086) — Westbury, New York
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in New York: - New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Babylon) — Babylon, New York
- NYU Langone's Perlmutter Cancer Center — Manhattan, New York
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(New Hyde Park) — New Hyde Park, New York
- Manhattan Hematology /Oncology Associates — New York, New York
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C (NY) — New York, New York
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in New York: - Local Institution - 0312 — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Local Institution - 1037 — Syracuse, New York
- Clinical Research Alliance — Westbury, New York
- White Plains Hospital — White Plains, New York
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in New York: - Research Site — Albany, New York
- Research Site — New York, New York
- Research Site — Syracuse, New York
Phase 3 Recruiting Academic/Other
The purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06144164
Sites in New York: - Memorial Sloan Kettering Commack (Limited Protocol Activities) — Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) — Uniondale, New York
Phase 3 Recruiting Industry
A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.
Sponsor: AstraZeneca
NCT ID: NCT07205822
Sites in New York: - Research Site — New York, New York
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Laura and Isaac Perlmutter Cancer Center / NYU Langone Health — New York, New York
- Columbia University Medical Center — New York, New York
- University of Rochester Wilmot Cancer Institute — Rochester, New York
- Montefiore Medical Center — The Bronx, New York
Phase 2 Recruiting Industry
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant…
Sponsor: Eli Lilly and Company
NCT ID: NCT07287098
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
- Wilmot Cancer Institute — Rochester, New York
- New York Cancer and Blood Specialists — Shirley, New York
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in New York: - Northwell Health — Lake Success, New York
- Laura & Isaac Perlmutter Cancer Center at NYC Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- North Shore Hematology Oncology Associate P.C. DBA New York Cancer and Blood Specialists — Shirley, New York
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in New York: - University of Rochester Medical Center — Rochester, New York
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in New York: - Columbia University Medical Center — New York, New York
- Memorial Sloan Kettering — New York, New York
Phase 2 Recruiting Academic/Other
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in New York: - Mount Sinai Union Square — New York, New York
- Mount Sinai Chelsea — New York, New York
- Mount Sinai West — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Montefiore Medical Center (Hutchinson Campus Tower 1) — The Bronx, New York
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in New York: - Columbia University Irving Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Industry
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…
Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT06998407
Sites in New York: - Avenzo Therapeutics Recruiting Site — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Sponsor: AstraZeneca
NCT ID: NCT05123482
Sites in New York: - Research Site — Commack, New York
- Research Site — New York, New York
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of…
Sponsor: Gilead Sciences
NCT ID: NCT06657222
Sites in New York: - Mount Sinai — New York, New York
Phase 2 Recruiting Academic/Other
This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03808337
Sites in New York: - Memorial Sloan Kettering Cancer Center @ Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295…
Sponsor: Accent Therapeutics
NCT ID: NCT06799065
Sites in New York: - NYU Longone Health (Long Island) — Long Island City, New York
- NYU Longone Health (Manhattan) — Manhattan, New York